IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: I. Luttichuys who wrote (1059)	6/25/1997 4:51:00 PM
From: Pseudo Biologist	of 1762

Bennet, are you saying that this is a general problem for any anti-CD4 antibody? If so, even the plan II, back up, Ab would be doomed as well; ditto for the OKT4A (J & J) and the Glaxo-Wellcome humanized anti-CD4's. Speaking in (very) general terms, one can argue that these anti-"many" (CD4, CD3, CD2 - meaning markers present in a large portion of the T-cell population) immunoregulating strategies are sort of shotgun first-generation approaches. As one understands the molecular basis of RA and other auto-immune conditions a bit better, it may be possible to come up with more selective targets that do not shut down an entire arm of the immune system. Still, as you suggested in a previous post, the information given in the press release and in statements to BioWorld leaves room for the notion that the CE9.1 situation is not beyond hope. PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next